Concentra (CON) Q4 FY25 earnings call

Concentra concluded FY25 with robust Q4 performance, surpassing full-year revenue and adjusted EBITDA guidance, driven by strong visit and rate growth in occupational health and double-digit organic expansion in its Onsite segment. The company is actively pursuing de novo expansion and bolt-on M&A, while navigating the final stages of its separation from Select and evaluating potential market entry into New York based on fee schedule revisions.